Alessandro Distante

Alessandro Distante

Auto-generated profile, based on publicly available information

Alessandro Distante

Euro Mediterranean Scientific Biomedical Institute (ISBEM), 72023 Mesagne, Italy

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
CNCosimo Neglia
Cosimo Neglia
AAAlberto Argentiero
Alberto Argentiero
PPPrisco Piscitelli
Prisco Piscitelli
NANadia Agnello
Nadia Agnello
RCRoberta Ciccarese
Roberta Ciccarese
PPPrisco Piscitelli
Prisco Piscitelli
Objectives: We aimed to analyze bone mineralization and the effect of different risk factors for osteoporosis in postmenopausal women. Methods: We found 4909 postmenopausal subjects within ≥10,000 records from the ROIS/EMEROS (Ionian and Salento Osteoporosis Registry/Euro Mediterranean Registry of Osteoporosis) registry, a population study carried out in an area characterized by heavy environmental pressure between Brindisi and Taranto from 2009 to 2016. All subjects were assessed via phalangeal quantitative ultrasound (QUS) to evaluate their bone mineralization (assessed via amplitude dependent speed of sound (AD-SoS)) and the association between demineralization and the presence of other conditions or risk factors. Results: Mean age was 64 ± 9.5 years and mean body mass index (BMI) was 28.7 ± 3.5 kg/m2. Pearson correlation analyses revealed a negative association between bone mineralization (AD-SoS) and BMI (p < 0.001). By using multivariate logistic regression analysis, we observed significant values of odds ratios (ORs) of osteoporosis (adjusted for age, physical activity, and the use of drugs known to increase the risk of fractures) in subjects with diabetes and obesity: 1.39 (confidence interval (CI): 1.05–1.83) and 1.46 (CI: 1.20–1.78), respectively. A statistically significant linear trend of higher ORs of osteoporosis was found for increasing values of BMI. Conclusions: Our study confirmed the high impact of obesity and type 1 and type 2 diabetes on osteoporosis.

19 November 2002
Verified
Conference Paper
Closed access
ESE. Stella
E. Stella
FMF. Musio
F. Musio
LVL. Vasanelli
L. Vasanelli
ADA. Distante
A. Distante

19 June 2009 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
PPPrisco Piscitelli
Prisco Piscitelli
ASAntonio Santoriello
Antonio Santoriello
Franco M BuonaguroFranco M Buonaguro
Franco M Buonaguro
MMMassimo Di Maio
Massimo Di Maio
GIGiovanni Iolascon
Giovanni Iolascon
TGthe CROM and the Human Health Foundation study group
the CROM and the Human Health Foundation study group
Objectives: We aimed to determine the incidence of women's breast cancer in Italy without using statistical approximations. Methods: We analyzed the national hospitalizations database at the Ministry of Health to calculate the number of major surgeries in Italian women (mastectomies and quadrantectomies) due to breast cancer between 2000 and 2005, overall and by age groups (<44, 45–64, 65–74 and ≥ 75 years old). Results: Over the six years examined, an overall number of 100,745 mastectomies and 168,147 quadrantectomies were performed. A total of 41,608 major surgeries due to breast cancer were performed in the year 2000 and this number rose to 47,200 in 2005, with a 13.4% increase over six years. Conclusion: by analyzing the hospitalizations database concerning major breast surgery, incidence of breast cancer in Italy was found to be 26.5% higher than the official estimations which have been computed using statistical models (namely 47,200 vs. 37,300 cases in year 2005).

24 August 2021 in Metabolites
Verified
Journal Article
Open access
PDF file
Andrea RagusaAndrea Ragusa
Andrea Ragusa
PRPietrina Romano
Pietrina Romano
Marcello Salvatore LenucciMarcello Salvatore Lenucci
Marcello Salvatore Lenucci
ECEmanuela Civino
Emanuela Civino
Daniele VergaraDaniele Vergara
Daniele Vergara
MICHELE MAFFIAMICHELE MAFFIA
MICHELE MAFFIA
Glycans play a fundamental role in several biological processes, such as cell–cell adhesion, signaling, and recognition. Similarly, abnormal glycosylation is involved in many pathological processes, among which include tumor growth and progression. Several highly glycosylated proteins found in blood are currently used in clinical practice as cancer biomarkers (e.g., CA125, PSA, and CA19-9). The development of novel non-invasive diagnostic procedures would greatly simplify the screening and discovery of pathologies at an early stage, thus also allowing for simpler treatment and a higher success rate. In this observational study carried out on 68 subjects diagnosed with either breast or lung cancer and 34 healthy volunteers, we hydrolyzed the glycoproteins in saliva and quantified the obtained free sugars (fucose, mannose, galactose, glucosamine, and galactosamine) by using high-performance anion-exchange chromatography with pulsed-amperometric detection (HPAEC-PAD). The glycosidic profiles were compared by using multivariate statistical analysis, showing differential glycosylation patterns among the three categories. Furthermore, Receiver Operating Characteristics (ROC) analysis allowed obtaining a reliable and minimally invasive protocol able to discriminate between healthy and pathological subjects.

DTDavide Di Tonno
Davide Di Tonno
CPCaterina Perlin
Caterina Perlin
ALAnna Chiara Loiacono
Anna Chiara Loiacono
LGLuca Giordano
Luca Giordano
LMLaura Martena
Laura Martena
AAAlberto Argentiero
Alberto Argentiero
Background: Phase 1 clinical trials represent a critical phase of drug development because new candidate therapeutic agents are tested for the first time on humans. Therefore, international guidelines and local laws have been released to mitigate and control possible risks for human health in agreement with the declaration of Helsinki and the international Good Clinical Practice principles. Despite numerous scientific works characterizing the registered clinical trials on ClinicalTrials.gov, the main features and trends of registered phase 1 clinical trials in Europe have not been investigated. This study is aimed at assessing the features and the temporal trend of distribution of phase 1 clinical studies, carried out in the five largest European countries over a ten-year period (2012–2021), and to evaluate the impact of the Italian regulatory framework on the activation of such studies. Methods: The main data and characteristics of phase 1 clinical studies registered on the ClinicalTrials.gov database for France, Germany, Italy, Spain and the United Kingdom have been investigated and subsequently compared. The above-mentioned countries were selected based on similarities in terms of demographic and Gross Domestic Product (GDP) data available on official government websites. (3) Results: A total number of 6878 phase 1 clinical trials were registered for the five selected countries in the ClinicalTrials.gov database during the ten years analyzed; the studies were predominantly randomized (39.33%) and for-profit (76.64%). The most represented area of investigations was oncology (52.15%), followed by hematology (24.99%) and immunology (12.04%). The variability observed between the analyzed countries showed that the UK, Germany and France presented the highest reduction in the number of phase 1 clinical trials, while for Spain and Italy, a stable/increased trend was observed, although with a lower number of trials registered on the ClinicalTrials.gov database. (4) Conclusions: Italy displayed the lowest number of registered phase 1 clinical trials, even though it showed a stable trend over the years. In this regard, the Italian regulatory framework must urgently be adapted to that of other European countries (Spain has been the first country to implement the new Regulation (EU) No 536/2014) and streamline the process of clinical trial application to increase the attractiveness of the country. Moreover, nonprofit phase 1 clinical trials (which represent 19.81% of the total number of phase 1 clinical trials registered in Italy vs. 80.19% of profit phase 1 clinical studies) should be promoted and supported by the institutions, even from a financial point of view, to allow independent researchers to develop new therapeutic drugs.

22 November 2002
Verified
Conference Paper
Closed access
FLfrancesco paolo lovergine
francesco paolo lovergine
ABA. Branca
A. Branca
GAGiovanni Attolico
Giovanni Attolico
ADA. Distante
A. Distante